NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) concerning possible violations of federal securities laws.
On March 30, 2017, Corbus Pharmaceuticals announced positive topline data from its Phase 2 study evaluating multiple doses of anabasum for the treatment of cystic fibrosis. While the company qualified the news as “positive,” the shares plummeted. Analysis from various reporters revealed that the safety and tolerability results were the result of the Company drawing most of the attention to an efficacy signal in a high-dose group. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.